Profiel
Marc E.
Uknis served as Vice President-Clinical Development at Achillion Pharmaceuticals, Inc. from 2018 to 2020.
He then worked as Chief Medical Officer at Gemini Therapeutics, Inc. from 2020 to 2021.
Uknis holds an MBA from George Washington University.
Eerdere bekende functies van Marc E. Uknis
Bedrijven | Functie | Einde |
---|---|---|
GEMI THER | Hoofd Techniek/Wetenschap/O&O | 11-04-2021 |
ACHILLION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 28-01-2020 |
Opleiding van Marc E. Uknis
George Washington University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
Gemini Therapeutics, Inc.
Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |